RhumbLine Advisers
QNRX

RhumbLine Advisers’s Quoin Pharmaceuticals QNRX Stock Holding History

RhumbLine Advisers’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10K Sell
1,521
-145
-9% -$1.31K ﹤0.01% 3807
2025
Q4 		$24K Buy
1,666
+456
+38% +$6.21K ﹤0.01% 3739
2025
Q3 		$8.7K Sell
1,210
-32
-3% -$249 ﹤0.01% 3869
2025
Q2 		$11.4K Buy
1,242
+49
+4% +$376 ﹤0.01% 3855
2025
Q1 		$9.55K Buy
1,193
+504
+73% +$6.63K ﹤0.01% 3841
2024
Q4 		$15.7K Buy
689
+95
+16% +$2.18K ﹤0.01% 3826
2024
Q3 		$10.5K Buy
594
+171
+40% +$3.6K ﹤0.01% 3883
2024
Q2 		$8.59K Buy
423
+314
+288% +$7.98K ﹤0.01% 4004
2024
Q1 		$3.6K Buy
109
+79
+263% +$7.79K ﹤0.01% 4024
2023
Q4 		$5.13K Buy
30
+4
+15% +$615 ﹤0.01% 3979
2023
Q3 		$3.78K Buy
26
+5
+24% +$1.04K ﹤0.01% 4025
2023
Q2 		$4.33K Buy
+21
New +$4.32K ﹤0.01% 4115

Other funds holding QNRX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

RhumbLine Advisers's QNRX Position: Q1 2026 in Review

RhumbLine Advisers reduced its Quoin Pharmaceuticals (QNRX) stake by 8.7% in Q1 2026, selling an estimated $1.31K and leaving 1,521 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #3807.

RhumbLine Advisers first reported a position in QNRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $24K in Q4 2025. 22 funds tracked by Wall St. Rank hold QNRX as of Q1 2026.

  • RhumbLine Advisers held 1,521 shares of Quoin Pharmaceuticals worth $10K as of Q1 2026.
  • RhumbLine Advisers sold 145 Quoin Pharmaceuticals shares in Q1 2026, an estimated $1.31K.
  • Quoin Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3807 holding.
  • RhumbLine Advisers first reported a position in Quoin Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Quoin Pharmaceuticals position peaked at $24K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.